Jade L. Kutzke, Pharm.D., (@kutzke_jade) summarizes the pathophysiology of acquired thrombotic thrombocytopenic purpura, outlines the current aTTP treatment pathway and identifies caplacizumab’s role in the current treatment approach of aTTP.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.